Sandoz, a Novartis division, is the global leader in biosimilar medicines. Our purpose is to discover new ways to improve and extend people’s lives. We pioneer novel approaches to drive access to medicine. Our portfolio comprises approximately 1000 molecules and out products reach well over 500 million patients. Sandoz Oncology offering is strongly complementary to leading innovative presence of Novartis Oncology.